Best selling drugs
Once more Humira® from AbbVie is the best selling drug of the quarter ($4,837M) despite headwinds in Europe from biosimilars Amgevita®, Amsparity®, Halimatoz®, Hefiya®, Hulio®, Hyrimoz®, Idacio® and Imraldi®. In the US Humira® will in 2023 lose market exclusivity to the biosimilars Amjevita®, Cyltezo®, Hyrimoz®, Hadlima®, Abrilada® and Hulio®. AbbVie upon acquisition of Allergan has become less dependent on the patent expiration of Humira®.
![](http://midgardfinance.com/img/logo_drugs/humira.png)
![](http://midgardfinance.com/img/2020-08/pharma2020q2_humira.png)
Keytruda® from Merck continues to receive FDA approvals and could perhaps be the best selling drug in the world before the end of next year.
![](http://midgardfinance.com/img/2020-08/pharma2020q2_best_selling.png)
The best selling antidiabetic and antiviral drug is still the GLP1 receptor agonist Trulicity® (dulaglutide) from Eli Lilly and Biktarvy® from Gilead Sciences, respectively. The combined sales of the GLP1 receptor agonists Ozempic® (once weekly subcutaneous semaglutide) and Victoza® (once daily subcutaneous liraglutide) from Novo Nordisk however exceed that of Trulicity®.
![](http://midgardfinance.com/img/logo_drugs/biktarvy.png)
![](http://midgardfinance.com/img/logo_drugs/trulicity.png)
Biktarvy® is currently the best selling oral drug ($1604M). In the future it could perhaps be the antidiabetic drug Rybelsus® (semaglutide) from Novo Nordisk. The antidiabetic drugs Januvia® and Janumet® from Merck reached combined annual peak sales of approximately $6B. The GLP1 receptor agonist semaglutide is a peptide, but it is available as a tablet (Rybelsus®) thanks to advances in oral peptide therapeutics.
Below the best selling drugs are visualized by company and by therapeutic area and vice versa.
![](http://midgardfinance.com/img/2020-08/pharma2020q2_groupATC3.1_rectDrug_colorATC3.1.png)
![](http://midgardfinance.com/img/2020-08/pharma2020q2_groupATC3.1_rectManufacturer_colorATC3.1.png)
![](http://midgardfinance.com/img/2020-08/pharma2020q2_groupManufacturer_rectDrug_colorManufacturer.png)
![](http://midgardfinance.com/img/2020-08/pharma2020q2_groupManufacturer_rectATC3.1_colorManufacturer.png)
Fastest growing drugs
The fastest growing drug value wise is the triple combination drug Trikafta®/Kaftrio® (ivacaftor+tezacaftor+elexacaftor) from Vertex Pharmaceuticals for the treatment of cystic fibrosis, which was approved by the FDA less than a year ago and by the EMA less than three months ago, followed by Keytruda® from Merck, Biktarvy® from Gilead Sciences, Dupixent® from Sanofi and Ozempic® from Novo Nordisk.
![](http://midgardfinance.com/img/2020-08/pharma2020q2_fastest_growing.png)
![](https://www.midgardfinance.com/10q10k/V/VRTX/VRTX_us-gaap.RevenueFromContractWithCustomerExcludingAssessedTax_us-gaap.ProductOrService_.png)
![](http://midgardfinance.com/img/logo_drugs/dupixent.png)
Ozempic® is the fastest growing drug percentage wise (~108%) followed by Venclexta® from AbbVie (~79%) and Dupixent® (~71%).
![](http://midgardfinance.com/img/2020-08/pharma2020q2_fastest_growing_blockbuster_percentagewise.png)
![](http://midgardfinance.com/img/logo_drugs/ozempic.png)
![](http://midgardfinance.com/img/logo_drugs/venclexta.png)
The details on semaglutide as a subcutaneous (Ozempic®) and oral (Rybelus®) antidiabetic drug and the clinical trials as an antiobesity drug are covered in different blog posts on Novo Nordisk.
![](http://midgardfinance.com/img/logo/400px-Novo_Nordisk.svg.png)